Asan Medical Center

Journal of Craniofacial Surgery Study Proves Planatome Blades Reduce Tissue Damage and Improve Diabetic Wound Healing from Surgical Incisions

Retrieved on: 
Jeudi, avril 18, 2024
Microsurgery, University, Rat, MMM, Inflammation, Hope, Risk, Craniofacial surgery, Diabetes, Ulsan College, Craniofacial, Surgeon, Doctor of Philosophy, Tearing, Research, Foot, Asan Medical Center, Patient, Immunodeficiency, Nano, MBA, Wound healing, Journal, Plastic, Dentistry

The study highlights the superior performance of Planatome blades in surgical procedures, particularly noting their ability to reduce incisional tissue damage, which reduced inflammation in diabetic rats.

Key Points: 
  • The study highlights the superior performance of Planatome blades in surgical procedures, particularly noting their ability to reduce incisional tissue damage, which reduced inflammation in diabetic rats.
  • The study found that using ultra-smooth blade technology significantly mitigated tissue injury, which, in turn, lessened inflammation and hasten wound healing.
  • Scar measurements proved a statistically significant reduction in scar width and scar tissue formation along the incisions made with Planatome blades.
  • The analysis demonstrated that incisions made using nano-polished Planatome blades resulted in more even, cleaner margins and less damage to surrounding tissue.

Healthcare Revolution 2024: Largest Industry Event Moves to Drive Superior Results in Healthcare and Medical Tourism

Retrieved on: 
Jeudi, avril 11, 2024
Korea Tourism Organization, Medical tourism, Organizational culture, AI, Health, Partnership, BEACH, PALM, Asan Medical Center, JD, EST, Culture, Medical director, Growth, Moonshot, Pharmaceutical industry

Learn exciting strategies to get ahead in the ever-evolving medical tourism landscape and ways to optimize your corporate health systems that no one else will teach you.

Key Points: 
  • Learn exciting strategies to get ahead in the ever-evolving medical tourism landscape and ways to optimize your corporate health systems that no one else will teach you.
  • This year's event themed "Optimizing Costs, Elevating Programs, and Achieving Superior Results," again focuses on the three key Moonshots launched a few years ago – Costs, Culture, and Care.
  • "HREV 2024 is another exciting time to get insights into new solutions to solve pressing challenges in today's healthcare landscape.
  • Healthcare Revolution 2024 is in partnership with the Medical Tourism Association and is sponsored by the Korea Tourism Organization, South Korea's official corporation in charge of the country's tourism industry.

Healthcare Revolution 2024: Largest Industry Event Moves to Drive Superior Results in Healthcare and Medical Tourism

Retrieved on: 
Jeudi, avril 11, 2024
Korea Tourism Organization, Medical tourism, Organizational culture, AI, Health, Partnership, BEACH, PALM, Asan Medical Center, JD, EST, Culture, Medical director, Growth, Moonshot, Pharmaceutical industry

Learn exciting strategies to get ahead in the ever-evolving medical tourism landscape and ways to optimize your corporate health systems that no one else will teach you.

Key Points: 
  • Learn exciting strategies to get ahead in the ever-evolving medical tourism landscape and ways to optimize your corporate health systems that no one else will teach you.
  • This year's event themed "Optimizing Costs, Elevating Programs, and Achieving Superior Results," again focuses on the three key Moonshots launched a few years ago – Costs, Culture, and Care.
  • "HREV 2024 is another exciting time to get insights into new solutions to solve pressing challenges in today's healthcare landscape.
  • Healthcare Revolution 2024 is in partnership with the Medical Tourism Association and is sponsored by the Korea Tourism Organization, South Korea's official corporation in charge of the country's tourism industry.

J INTS BIO, Phase 1/2 study of 'JIN-A02', a Novel Oral 4th Generation EGFR TKI, accepted for presentation at the upcoming American Association for Cancer Research 2024 meeting in USA (AACR 2024)

Retrieved on: 
Lundi, février 26, 2024
NSCLC, Traffic barrier, Severance Hospital, EGFR, ESMO, ASCO, Permeability, Catholic University of Korea, National Cancer Center, Hospital, Asan Medical Center, AACR, Society, University, Seoul National University Hospital, Patient, Clinical trial, Oncology, Mutation, Trial of the century, Cancer, Pharmaceutical industry

J INTS BIO will present a poster during the "Phase I Clinical Trials in Progress" session, which will be held on April 8 from 1:30 to 5:00 p.m.

Key Points: 
  • J INTS BIO will present a poster during the "Phase I Clinical Trials in Progress" session, which will be held on April 8 from 1:30 to 5:00 p.m.
  • The topic of the presentation is "Phase 1/2 clinical trial of JIN-A02, a 4th generation EGFR-TKI for 3rd generation EGFR-TKI resistant patients in EGFR mutated advanced/metastatic non-small cell lung cancer".
  • In August last year, J INTS BIO registered the first patient for the global Phase 1/2 clinical trial of 'JIN-A02' at Severance Hospital in Korea.
  • A J INTS BIO official said, "The global clinical trial for 'JIN-A02' is progressing well and is receiving interest in the global market."

J INTS BIO, Phase 1/2 study of 'JIN-A02', a Novel Oral 4th Generation EGFR TKI, accepted for presentation at the upcoming American Association for Cancer Research 2024 meeting in USA (AACR 2024)

Retrieved on: 
Lundi, février 26, 2024
NSCLC, Traffic barrier, Severance Hospital, EGFR, ESMO, Multimedia, ASCO, Permeability, Catholic University of Korea, National Cancer Center, Hospital, Asan Medical Center, AACR, Society, University, Seoul National University Hospital, Patient, Clinical trial, Oncology, Mutation, Trial of the century, Cancer, Pharmaceutical industry

J INTS BIO will present a poster during the "Phase I Clinical Trials in Progress" session, which will be held on April 8 from 1:30 to 5:00 p.m.

Key Points: 
  • J INTS BIO will present a poster during the "Phase I Clinical Trials in Progress" session, which will be held on April 8 from 1:30 to 5:00 p.m.
  • The topic of the presentation is "Phase 1/2 clinical trial of JIN-A02, a 4th generation EGFR-TKI for 3rd generation EGFR-TKI resistant patients in EGFR mutated advanced/metastatic non-small cell lung cancer".
  • In August last year, J INTS BIO registered the first patient for the global Phase 1/2 clinical trial of 'JIN-A02' at Severance Hospital in Korea.
  • A J INTS BIO official said, "The global clinical trial for 'JIN-A02' is progressing well and is receiving interest in the global market."

Health On Cloud Expands Global Presence with Innovative Metaverse Medical Platform

Retrieved on: 
Jeudi, décembre 28, 2023
Cloud, Cardiology, Multimedia, SHA, Developed country, Research, WHO, Amazon, ICT, Patient safety, Feasibility study, Education, CIO, Society, Cardiothoracic surgery, Genomics, Asan Medical Center, HOC, CLOUD, NHS foundation trust, University of Manchester, Pharmaceutical industry

SEOUL, South Korea, Dec. 28, 2023 /PRNewswire/ -- Health On Cloud, an innovator in advanced healthcare solutions, is excited to announce the global expansion of its revolutionary metaverse medical consultation platform, CURISALL, along with its medical education platform, MEDTIS.

Key Points: 
  • SEOUL, South Korea, Dec. 28, 2023 /PRNewswire/ -- Health On Cloud, an innovator in advanced healthcare solutions, is excited to announce the global expansion of its revolutionary metaverse medical consultation platform, CURISALL, along with its medical education platform, MEDTIS.
  • Health On Cloud is focused on deploying a globally connected Virtual University Hospital consisting of (i) Meta-Versity; and (ii) Cloud Hospital.
  • In line with WHO's vision, Health On Cloud envisions creating a world where no one is excluded from medical services.
  • Additionally, by collecting medical data through remote consultations, Health On Cloud aims to contribute to the latest advancements in healthcare technology.

Health On Cloud Expands Global Presence with Innovative Metaverse Medical Platform

Retrieved on: 
Jeudi, décembre 28, 2023
Cloud, Cardiology, SHA, Developed country, Research, WHO, Amazon, ICT, Patient safety, Feasibility study, Education, CIO, Society, Cardiothoracic surgery, Genomics, Asan Medical Center, HOC, CLOUD, NHS foundation trust, University of Manchester, Pharmaceutical industry

SEOUL, South Korea, Dec. 28, 2023 /PRNewswire/ -- Health On Cloud, an innovator in advanced healthcare solutions, is excited to announce the global expansion of its revolutionary metaverse medical consultation platform, CURISALL, along with its medical education platform, MEDTIS.

Key Points: 
  • SEOUL, South Korea, Dec. 28, 2023 /PRNewswire/ -- Health On Cloud, an innovator in advanced healthcare solutions, is excited to announce the global expansion of its revolutionary metaverse medical consultation platform, CURISALL, along with its medical education platform, MEDTIS.
  • Health On Cloud is focused on deploying a globally connected Virtual University Hospital consisting of (i) Meta-Versity; and (ii) Cloud Hospital.
  • In line with WHO's vision, Health On Cloud envisions creating a world where no one is excluded from medical services.
  • Additionally, by collecting medical data through remote consultations, Health On Cloud aims to contribute to the latest advancements in healthcare technology.

Universal Display Corporation Announces Recipients of the 2023 UDC Innovative Research and Pioneering Technology Awards at IMID Korea

Retrieved on: 
Mardi, août 29, 2023
Consumer Electronics, Other Energy, Technology, Audio, Video, Energy, Hardware, Telecommunications, Lighting, Electronics, IMID, Health care, Organic electronics, Universal Display Corporation, Gachon University, Electronics and Telecommunications Research Institute, Multimedia, Research, PHOLED, KAIST, Asan Medical Center, ETRI, 1957 International Meeting of Communist and Workers Parties, UDC, Sungkyunkwan University, OLED, KIDS, Knowledge, Television, Cryptocurrency, Diabetes

Universal Display Corporation (Nasdaq: OLED) (UDC), enabling energy-efficient displays and lighting with its UniversalPHOLED® technology and materials, announced today the recipients of the UDC Innovative Research Award in Organic Electronics & Display and the UDC Pioneering Technology Award in Organic Electronics & Display.

Key Points: 
  • Universal Display Corporation (Nasdaq: OLED) (UDC), enabling energy-efficient displays and lighting with its UniversalPHOLED® technology and materials, announced today the recipients of the UDC Innovative Research Award in Organic Electronics & Display and the UDC Pioneering Technology Award in Organic Electronics & Display.
  • These awards were presented at the 23rd International Meeting on Information Display (IMID 2023) conference on August 24th in Busan, Korea by Dr. Mike Weaver, Vice President of PHOLED R&D of Universal Display Corporation.
  • We congratulate the UDC Innovative Research Award and UDC Pioneering Technology Award recipients and applaud all the researchers for their contributions in the growing field of organic electronics and displays.
  • The UDC awards recognize outstanding individuals or teams that have demonstrated innovative ideas or research initiatives impacting the organic electronic and display industries.

Apollon and MIT Commence Collaboration to Develop Continuous Non-Invasive Glucose Monitoring Technology

Retrieved on: 
Lundi, août 21, 2023
Medical Supplies, Health, Start-Up, Diabetes, Professional Services, University, Education, Clinical Trials, CGM, Inc., Biological engineering, Science Advances, Asan Medical Center, Department of Mechanical Engineering, Imperial College London, MIT, Bangladesh Technical Education Board, Mechanical, MARD, Miniaturization, Samsung, Blood, Himawari (satellites), FDA, Skin, Massachusetts Institute of Technology, Medical device, Apollon

Dr. Peter So, Professor of Mechanical and Biological Engineering and Director of the MIT LBRC, and Dr. Jeonwoong Kang of the Department of Mechanical Engineering will lead the collaboration.

Key Points: 
  • Dr. Peter So, Professor of Mechanical and Biological Engineering and Director of the MIT LBRC, and Dr. Jeonwoong Kang of the Department of Mechanical Engineering will lead the collaboration.
  • As a result of Apollon's expertise in Raman diagnostics and spectrometer miniaturization, MIT will invite Dr. Youngkyu Kim of Apollon as a visiting scientist.
  • Dr. Kang published a paper in the prestigious journal Science Advances in 2020 that directly measured glucose concentration without drawing blood by irradiating the skin with laser light.
  • It was funded by the National Institutes of Health and Samsung Advanced Institute of Technology.

Clinical Trials Supply & Logistics Industry Report 2023: Heavy Investments by Key Companies in Advanced Technologies Driving Growth - Opportunities and Forecasts to 2027 - ResearchAndMarkets.com

Retrieved on: 
Vendredi, juin 30, 2023
Health, Clinical Trials, Vaccine, Human, Obesity, Drug development, Diabetes, Internet, RFID, Clinical trial, Ageing, Cancer, Pharmaceutical Research and Manufacturers of America, Pharmacy, Research, Medicine, AMC, Government, Asan Medical Center, Organization, Animal, Growth, WHO, FDA, Pharmaceutical industry

The "Clinical Trials Supply & Logistics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Clinical Trials Supply & Logistics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027" report has been added to ResearchAndMarkets.com's offering.
  • A clinical trial is a process in which several experiments, tests, or studies are performed on animals and humans to analyze the results.
  • Clinical trials are split into two types that are observational studies and interventional trials.
  • Heavy investments by several companies in advanced technologies and logistics are propelling the growth of the market.